Public health authorities and drug manufacturers need to be open regarding the side effects of coronavirus vaccine

Public health authorities and drug manufacturers need to be open regarding the side effects of coronavirus vaccines, doctors say. Doctors met with CDC advisers as states plan to administer doses as early as next month. Both Pfizer and Moderna vaccines need two doses at different intervals. Participants in the trials registered high fever, body aches, extreme headaches, day-long fatigue after the shots. “We need to make patients aware that this will not be a walk in the park,” says Dr. Sandra Fryhofer. Nurse practitioners recommend that drug manufacturers should use terms such as “response” instead of “adverse reaction” to explain side effects. “If this proves to work, people are going to toughen up,” says the nurse practitioner.

“These are immune responses,” says Stinchfield, a former member of the committee who voted. “If you feel something after vaccination, expect to feel that” Pfizer and its partner BioNTech applied for an emergency license for their coronavirus vac.

Reference

Doctors say CDC should warn people the side effects from Covid vaccine shots won’t be ‘a walk in the park’. https://www.cnbc.com/2020/11/23/covid-vaccine-cdc-should-warn-people-the-side-effects-from-shots-wont-be-walk-in-the-park-.html

Both the Pfizer vaccine and the Moderna vaccine were developed with new technology

Both the Pfizer vaccine and the Moderna vaccine were developed with new technology that uses messenger RNA. Neither Pfizer nor Moderna has reported any serious safety issues in their trials so far. An independent group of advisers will review vaccine data to the FDA and the CDC. The FDA will decide whether to grant authorization for emergency use; then, the CDC will decide who gets the vaccine. The advisory committees do not have the authority to make decisions, but they follow other groups’ recommendations, Salmon says. The decision does not end at the time of recommendation, Lee says. “We are always in creating new data as it emerges, so it can ch so that,” she says. Back To the pageYou came from: The page you were from. The CDC will craft guidance for the CDC about prioritizing, who receives the vaccine. First, Salmon said.


The public will view trial data and observe discussions as the Vaccines and Related Biological Products Advisory Committee conducts its review in early December. “It will include public deliberation, and that is a good thing,” Salmon said. Salmon added that this type of transparency would be a crucial way to bolster public trust and combat misinformation. This is particularly important because the pandemic has become heavily politicized.


Reference
Will the Covid vaccine be safe? What the scientists want to see.https://www.nbcnews.com/health/health-news/will-covid-vaccine-be-safe-what-scientists-want-see-n1248466
What is mRNA? How Pfizer and Moderna tapped new tech to …. https://www.nbcnews.com/science/science-news/what-mrna-how-pfizer-moderna-tapped-new-tech-make-coronavirus-n1248054
What Is Homework’s Purpose in a Pandemic?. http://www.ascd.org/publications/newsletters/education-update/oct20/vol62/num10/What-Is-Homework’s-Purpose-in-a-Pandemic%C2%A2.aspx

Interleukin-1 has been involved as a mediator of chronic pericarditis

Interleukin-1 has been involved as a mediator of chronic pericarditis. A phase 3 trial of rilonacept was performed in patients with acute symptoms and systemic inflammation. During the run-in period, the median time for pain resolution or near-resolution was 5 days, and the median time for normalization of CRP was 7 days. Injection site reactions and upper respiratory tract infections were the most common adverse events. Among patients with chronic periecarditis, treatment resulted in rapid resolution and a slightly lower risk of recurrence than placebo. The most common side effects were injection site reactions and upper respiratory tract infections.

Reference

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. https://www.nejm.org/doi/full/10.1056/NEJMoa2027892

Guidelines prescribe that one or more antiarrhythmic medications

Guidelines prescribe that one or more antiarrhythmic medications be tested before catheter ablation is considered in patients with atrial fibrillation. First-line ablation could be more effective in preserving sinus rhythm, we’ve discovered. Severe adverse effects resulted in 5 patients who underwent ablation and 6 patients who prescribed antiarrhythmic drug treatment. Patients undergoing initial care for symptomatic, paroxysmal atrial fibrillation had a slightly lower risk of recurrence with catheter cryoballoon ablation than with antiarrHythmicDrug, as measured by continuous heart rhythm testing. The median ratio of time of atrial fibrillation was 0 per cent (interquartile scale, 0 to 0.08) with ablation and 0.13 per cent with drug treatment compared to 0.60 per cent with ablated therapy.

Reference

Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. https://www.nejm.org/doi/full/10.1056/NEJMoa2029980

It is possible to forget that COVID-19 is only a relatively young virus

It is possible to forget that COVID-19 is only a relatively young virus. And with that, experts are also struggling to find ways to handle it. Today, a recent report indicates that one possible cure for the virus may be found in your local pharmacy: traditional sleep aid melatonin.

The November study, which was published in the journal PLOS Biology, analyzed patient results from the Cleveland Clinic COVID-19 registry.1 Researcher found that melatonin use was related to an approximately 30% reduced risk of positive testing for SARS-CoV-2, the virus that triggers COVID-19, after age, race, smoking history, and comorbidity-adjusted scientists. The figures for people in some communities were also higher: Afro-Americans had a 52 percent reduced chance of positive results, while those with diabetes were at a 48 percent lower risk.
Reference

Researchers Identify Melatonin as Possible COVID-19 Treatment. https://www.verywellhealth.com/melatonin-possible-covid-19-treatment-5087816

Fluvoxamine antidepressant avoids the deterioration of COVID-19 infections

In a clinical trial performed by the Washington University School of Medicine in St. Louis, fluvoxamine was associated with a placebo in 152 adult outpatients afflicted with coronavirus. They are hoping to start a more significant trial in the next few weeks.

After 15 days, none of the 80 subjects who got fluvoxamine were critically ill, although six patients who received the placebo did. Of the six, four were hospitalized for periods ranging from four to 21 days. All of them were on the ventilator for ten days.

Although the sample size was limited, the researchers say the findings are statistically significant and that fluvoxamine merits further study as a COVID-19 therapy. They are hoping to start a more significant trial in the next few weeks.

“Patients who take fluvoxamine did not experience severe respiratory issues or need hospitalization for complications with lung function,” said Eric J. Lenze, MD, of the Washington University School of Medicine. “Most of the investigational therapies for COVID-19 have been focused on very ill patients, but it is often necessary to identify treatments that keep patients from being sick enough to need extra oxygen or to have to go to the hospital. Our analysis shows that fluvoxamine can help fill that niche.”

Reference

Antidepressant may prevent severe COVID-19, U.Va. research finds. https://wtop.com/virginia/2020/11/antidepressant-may-prevent-severe-covid-19-u-va-research-finds/

Type 2 diabetes can be cured

Shao Changchun, a traditional Chinese medicine practitioner, claims that type 2 diabetes can be cured and healed by the patient. He claims about half of the 130,000 people he has shown were relieved of diabetes. Photo: Simon SongShao Changchun, a traditional Chinese medicine practitioner, claims that type 2 diabetes can be cured and treated by the patient. He claims about half of the 130,000 people he has seen have been cured of diabetes.

Shao Changchun, a traditional Chinese medicine practitioner, claims that type 2 diabetes can be cured and healed by the patient. He claims about half of the 130,000 people he has seen have been cured of diabetes.

Western medicine sees diabetes as an incurable condition requiring lifetime insulin infusion and other drugs to keep it under control.

Chief of Beijing Changchun TCM Hospital in Beijing, founded three years ago to specialize in treating type 2.

Reference
World Diabetes Day 2020: traditional Chinese medicine can cure Type 2 diabetes, not just control it, doctor heading Beijing hospital says. https://www.scmp.com/lifestyle/health-wellness/article/3109687/world-diabetes-day-traditional-chinese-medicine-can-cure

The spread of the Covid-19 among members in a family group

The spread of the Covid-19 among members in a family group after one individual is infected is “common” and occurs quickly after illness onset, relating to new research through the US Centers for Disease Control and Prevention.

The person exposed or suspected of experiencing Covid-19 should always be isolated before getting tested, and before test outcomes get back to protect others in the home, said the analysis, published Friday when looking at the CDC’s Morbidity and Mortality Weekly Report.

“Because prompt isolation of persons with #COVID-19 can lessen household transmission, persons who suspect which they could have COVID-19 should isolate, stay in the home, and employ an independent bedroom and bathroom if feasible,” wrote a CDC-led team of researchers.
All people in family members should also wear masks all of the time per space, the group said.

Referencehttps://www.cnn.com/2020/10/30/health/household-spread-covid-19-wellness/index.html
Household spread of Covid-19 is common and quick, a new CDC study finds. https://www.cnn.com/2020/10/30/health/household-spread-covid-19-wellness/index.html.

Regeneron Pharmaceuticals has paused critically ill COVID-19 patients’ enrollment

Regeneron Pharmaceuticals has paused critically ill COVID-19 patients’ enrollment with its trial studying the antibody cocktail treatment, which was fond of President Trump earlier this month. The choice is because of potential safety concerns.
The drugmaker on Friday said it was suspending the enrollment of hospitalized #COVID-19 patients requiring high-flow oxygen or mechanical ventilation after an unbiased monitoring committee observed “a potential safety signal and an unfavorable risk/benefit profile at the moment.”

The enrollment of individuals in this category should be on hold, pending the collection and evaluation of additional data.

Trials continue to test the antibody cocktail in hospitalized patients necessitating little if any extra oxygen. Other trials involving mild or moderately ill patients also can move ahead.

The drug has revealed encouraging outcomes. Regeneron on Wednesday said early data confirmed the therapy lowered COVID-19 related medical visits by 57 percent.

Regeneron earlier this month asked the foodstuff and Drug Administration for emergency approval and said it could make doses accessible to the American people free of charge. The drugmaker said it might have sufficient doses for 300,000 people when looking at the coming months.

Reference

Regeneron stops enrolling critically ill COVID-19 patients …. https://news.immitate.com/2020/10/30/regeneron-stops-enrolling-critically-ill-covid-19-patients-for-antibody-drug-trial-thehill-the-hill/.